138 related articles for article (PubMed ID: 34268949)
1. CDCA2 triggers in vivo and in vitro proliferation of hepatocellular carcinoma by activating the AKT/CCND1 signaling.
Li J; Chen Y; Wang X; Wang C
J BUON; 2021; 26(3):882-888. PubMed ID: 34268949
[TBL] [Abstract][Full Text] [Related]
2. CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo.
Feng Y; Qian W; Zhang Y; Peng W; Li J; Gu Q; Ji D; Zhang Z; Wang Q; Zhang D; Sun Y
BMC Cancer; 2019 Jun; 19(1):576. PubMed ID: 31196027
[TBL] [Abstract][Full Text] [Related]
3. CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.
Li K; Fan T; Shi Z; Jiang H
Anal Cell Pathol (Amst); 2022; 2022():9912254. PubMed ID: 36588796
[TBL] [Abstract][Full Text] [Related]
4. Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.
Wang J; Liu X; Chu H; Chen J
PeerJ; 2022; 10():e13535. PubMed ID: 35694386
[TBL] [Abstract][Full Text] [Related]
5. CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma.
Wang S; Cao K; Liao Y; Zhang W; Zheng J; Li X; Huang M; Zhong Y; Hu X; Chen D; Wang Y
Oncogene; 2021 Jun; 40(25):4368-4383. PubMed ID: 34103686
[TBL] [Abstract][Full Text] [Related]
6. E2F3/CDCA2 reduces radiosensitivity in gastric adenocarcinoma by activating PI3K/AKT pathway.
Gao J; Wang H; Qiu X; Tang J
Br J Radiol; 2023 Dec; 96(1152):20230477. PubMed ID: 37750838
[TBL] [Abstract][Full Text] [Related]
7. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
8. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.
Ma XL; Shen MN; Hu B; Wang BL; Yang WJ; Lv LH; Wang H; Zhou Y; Jin AL; Sun YF; Zhang CY; Qiu SJ; Pan BS; Zhou J; Fan J; Yang XR; Guo W
J Hematol Oncol; 2019 Apr; 12(1):37. PubMed ID: 30971294
[TBL] [Abstract][Full Text] [Related]
9. Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3β Signaling Pathway in Human Hepatocellular Carcinoma.
Zhou LJ; Mo YB; Bu X; Wang JJ; Bai J; Zhang JW; Cheng AB; Ma JH; Wang YW; Xie YX
Cell Physiol Biochem; 2018; 50(3):851-867. PubMed ID: 30355923
[TBL] [Abstract][Full Text] [Related]
10. Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway.
Hsieh YH; Hsieh SC; Lee CH; Yang SF; Cheng CW; Tang MJ; Lin CL; Lin CL; Chou RH
Oncotarget; 2015 Oct; 6(33):34859-74. PubMed ID: 26472188
[TBL] [Abstract][Full Text] [Related]
11. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
[TBL] [Abstract][Full Text] [Related]
12. CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients.
Shi R; Zhang C; Wu Y; Wang X; Sun Q; Sun J; Xia W; Dong G; Wang A; Jiang F; Xu L
Oncotarget; 2017 Mar; 8(12):19768-19779. PubMed ID: 28423619
[TBL] [Abstract][Full Text] [Related]
13. STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway.
Wu JZ; Jiang N; Lin JM; Liu X
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2977-2985. PubMed ID: 32271415
[TBL] [Abstract][Full Text] [Related]
14. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CDCA2 in human squamous cell carcinoma: correlation with prevention of G1 phase arrest and apoptosis.
Uchida F; Uzawa K; Kasamatsu A; Takatori H; Sakamoto Y; Ogawara K; Shiiba M; Bukawa H; Tanzawa H
PLoS One; 2013; 8(2):e56381. PubMed ID: 23418564
[TBL] [Abstract][Full Text] [Related]
16. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
17. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
18. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
19. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA PTTG3P functions as an oncogene by sponging miR-383 and up-regulating CCND1 and PARP2 in hepatocellular carcinoma.
Zhou Q; Zhang W; Wang Z; Liu S
BMC Cancer; 2019 Jul; 19(1):731. PubMed ID: 31340767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
